留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝细胞癌伴门静脉左支癌栓形成多学科综合治疗1例报告

杨季红 陈国想 周茉 赵继森 王元 周元龙

杨季红, 陈国想, 周茉, 等. 肝细胞癌伴门静脉左支癌栓形成多学科综合治疗1例报告[J]. 临床肝胆病杂志, 2021, 37(3): 666-669. DOI: 10.3969/j.issn.1001-5256.2021.03.031
引用本文: 杨季红, 陈国想, 周茉, 等. 肝细胞癌伴门静脉左支癌栓形成多学科综合治疗1例报告[J]. 临床肝胆病杂志, 2021, 37(3): 666-669. DOI: 10.3969/j.issn.1001-5256.2021.03.031
YANG JH, CHEN GX, ZHOU M, et al. Multidisciplinary treatment of hepatocellular carcinoma with tumor thrombosis in the left portal vein: A case report [J]. J Clin Hepatol, 2021, 37(3): 666-669. DOI: 10.3969/j.issn.1001-5256.2021.03.031
Citation: YANG JH, CHEN GX, ZHOU M, et al. Multidisciplinary treatment of hepatocellular carcinoma with tumor thrombosis in the left portal vein: A case report [J]. J Clin Hepatol, 2021, 37(3): 666-669. DOI: 10.3969/j.issn.1001-5256.2021.03.031

肝细胞癌伴门静脉左支癌栓形成多学科综合治疗1例报告

DOI: 10.3969/j.issn.1001-5256.2021.03.031
详细信息
    作者简介:

    杨季红(1976—),男,主要从事临床肝胆、胰腺疾病的临床研究

    通讯作者:

    周元龙,448156636@qq.com

  • 利益冲突声明:所有作者均声明不存在利益冲突。
  • 作者贡献声明:杨季红负责查找阅读及总结文献,分析资料,撰写论文;陈国想、周茉、赵继森、王元负责收集病例治疗以及指导论文撰写;周元龙负责拟定写作思路,指导撰写文章并最后定稿。
  • 中图分类号: R735.7

Multidisciplinary treatment of hepatocellular carcinoma with tumor thrombosis in the left portal vein: A case report

  • 图  1  腹部门静脉成像

    注:箭头所示为门静脉左支癌栓。

    图  2  腹部增强CT

    注:箭头所示为门静脉左支癌栓。

    图  3  上腹部MRI增强

    注:箭头所示为肿瘤最大直径。

    图  4  上腹部MRI增强矢状位

    注:箭头所示为肿瘤最大直径。

    图  5  离体标本

    图  6  离体标本肿瘤切面

    图  7  2018年7月5日TACE术前造影

    注:箭头所示为复发肿瘤。

    图  8  2018年7月5日TACE术后造影

    图  9  2018年9月19日TACE术中造影

    注:箭头所示考虑复发肿瘤。

    图  10  2018年9月19日TACE术后造影

    图  11  2019年4月23日增强核磁显示胆总管下段截断伴胆道梗阻

    注:箭头所示为胆总管下段截断。

    图  12  PTCD术中造影

    注:箭头所示为胆总管梗阻,胆汁引流不畅。

    图  13  PTCD术后造影

    注:PTCD术后,胆汁引流通畅(箭头)。

  • [1] RHIM H, LIM HK, CHOI D. Current status of radiofrequency ablation of hepatocellular carcinoma[J]. World J Gastrointest Surg, 2010, 2(4): 128-136. DOI: 10.4240/wjgs.v2.i4.128
    [2] CHENG SQ, WU MC, CHEN H, et al. Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein[J]. Hepatogastroenterology, 2007, 54(74): 499-502.
    [3] HUO L, WEI WX, YAN ZL, et al. Short-term and long-term outcomes of liver resection for HCC patients with portal vein tumor thrombus[J].Cell Biosci, 2019, 9: 23.
    [4] ZHANG ZY, DONG KS, ZHANG EL, et al. Resection might be a meaningful choice for hepatocellular carcinoma with portal vein thrombosis: A systematic review and meta-analysis[J]. Medicine (Baltimore), 2019, 98(50): e18362. DOI: 10.1097/MD.0000000000018362
    [5] YU JI, CHOI GS, LIM DH, et al. Versus treatment of naïve HCC combined with segmental or subsegmental portal vein tumor thrombosis: Liver resection TACE followed by radiotherapy[J]. Anticancer Res, 2018, 38: 4919-4925. DOI: 10.21873/anticanres.12808
    [6] LIANG L, CHEN TH, LI C, et al. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. HPB (Oxford), 2018, 20(12): 1119-1129. DOI: 10.1016/j.hpb.2018.06.1804
    [7] LE Y, SHEN JX, ZHANG YF, et al. Transarterial chemoembolization related to good survival for selected patients with advanced hepatocellular carcinoma[J]. J Cancer, 2019, 10(3): 665-671. DOI: 10.7150/jca.28528
    [8] LV WF, LIU KC, LU D, et al. Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis[J]. Cancer Manag Res, 2018, 10: 4719-4726. DOI: 10.2147/CMAR.S166527
    [9] de BAERE T, ARAI Y, LENCIONI R, et al. Treatment of liver tumors with lipiodol TACE: Technical recommendations from experts opinion[J]. Cardiovasc Intervent Radiol, 2016, 39(3): 334-343. DOI: 10.1007/s00270-015-1208-y
    [10] HUO YR, CHAN MV, CHAN C. Resection plus post-operative adjuvant transcatheter arterial chemoembolization (TACE) compared with resection alone for hepatocellular carcinoma: A systematic review and Meta-analysis[J]. Cardiovasc Intervent Radiol, 2020, 43(4): 572-586. DOI: 10.1007/s00270-019-02392-6
    [11] LIU S, GUO L, LI H, et al. Postoperative adjuvant trans-arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Ann Surg Oncol, 2018, 25(7): 2098-2104. DOI: 10.1245/s10434-018-6438-1
    [12] Chinese Society of Liver Cancer, Chinese Medical Doctor Association. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018)[J]. J Clin Hepatol, 2019, 35(4): 737-743.(in Chinese)

    中国医师协会肝癌专业委员会. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版)[J]. 临床肝胆病杂志, 2019, 35(4): 737-743.
    [13] WANG Z, REN Z, CHEN Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: A randomized controlled study[J]. Clin Cancer Res, 2018, 24(9): 2074-2081. DOI: 10.1158/1078-0432.CCR-17-2899
    [14] WEI W, JIAN PE, LI SH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: A randomized clinical trial of efficacy and safety[J]. Cancer Commun (Lond), 2018, 38(1): 61. DOI: 10.1186/s40880-018-0331-y
    [15] YAN D. Interpretation of 2018 CSCO guidelines for diagnosis and treatment of primary liver cancer—hepatic arterial interventional therapy[J/CD]. Electronic J Liver Tumor, 2018, 5(3): 4-7.(in Chinese)

    闫东. 2018《CSCO原发性肝癌诊疗指南》解读——肝动脉介入治疗部分[J/CD]. 肝癌电子杂志, 2018, 5(3): 4-7.
    [16] SAMARIN J, LAKETA V, MALZ M, et al. PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells[J]. Hepatology, 2016, 63(3): 813-826. DOI: 10.1002/hep.28357
    [17] ZHANG X, WANG K, WANG M, et al. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: A systematic review and Meta-analysis[J]. Oncotarget, 2017, 8(17): 29416-29427. DOI: 10.18632/oncotarget.15075
    [18] TAKANO M, KOKUDO T, MIYAZAKI Y, et al. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(42): 9445-9450. DOI: 10.3748/wjg.v22.i42.9445
    [19] YUAN J, YIN X, TANG B, et al. Transarterial chemoembolization (TACE) combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumor thrombus: A Propensity score matching study[J]. Biomed Res Int, 2019, 2019: 2141859.
    [20] HEO YA, SYED YY. Regorafenib: A review in hepatocellular carcinoma[J]. Drugs, 2018, 78(9): 951-958. DOI: 10.1007/s40265-018-0932-4
    [21] BRUIX J, QIN SK, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389: 56-66. DOI: 10.1016/S0140-6736(16)32453-9
    [22] SINN DH, CHOI GS, PARK HC, et al. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients[J]. PLoS One, 2019, 14(1): e0210730. DOI: 10.1371/journal.pone.0210730
    [23] LIU PH, HUO TI, MIKSAD RA. Hepatocellular carcinoma with portal vein tumor involvement: Best management strategies[J]. Semin Liver Dis, 2018, 38(3): 242-251. DOI: 10.1055/s-0038-1666805
  • 加载中
图(13)
计量
  • 文章访问数:  35
  • HTML全文浏览量:  14
  • PDF下载量:  28
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-09-02
  • 修回日期:  2020-11-03
  • 刊出日期:  2021-03-16
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回